Hollenhorst plaques H34.2

Last updated on: 20.09.2024

Dieser Artikel auf Deutsch

History
This section has been translated automatically.

The first records of a bright retinal embolism can be found as early as 1927 by T. Harrison Butler (Kaufman 2024).

Robert W. Hollenhorst described the Hollenhorst plaques named after him in 1958. Independently of this, the German researchers Witmer and Schmid also described these retinal plaques in the same year (Graff-Radford 2015).

Definition
This section has been translated automatically.

Hollenhorst plaques (HP) are cholesterol emboli that are localized in the retina of the eye (Herold 2020).

Occurrence/Epidemiology
This section has been translated automatically.

According to Kaufman (2024), the prevalence of retinal embolisms in people over the age of 49 is 1.4%. The prevalence also increases with age. HPs account for around 80 % of all retinal embolisms.

Cholesterol crystals in retinal vessels are found in approx. 11% of patients with cholesterol embolism syndrome (Endres 2022).

Patients with arterial branch occlusion (AAV) are usually between 50 and 60 years of age. Men are more frequently affected than women (Erb 2011).

Etiopathogenesis
This section has been translated automatically.

Hollenhorst plaques are caused by atheromatous diseases of the carotid artery or the aortic arch (Graff-Radford 2015).

The plaques consist of cholesterol and are recognizable as crystalline deposits (Kasper 2015).

HPs have been found to be significantly associated with arterial hypertension, a history of vascular surgery, general vascular disease and smoking (history of smoking) (Kaufman 2024).

Pathophysiology
This section has been translated automatically.

The source of retinal emboli are ulcerating plaques distal to the bifurcation of the common carotid artery into its outer and inner branches (Kaufman 2024).

Localization
This section has been translated automatically.

Hollenhorst plaques are typically localized in the retina of the eye (Herold 2020). However, localizations of the CNS, liver, pancreas, spleen, prostate, testicles, adrenal gland and thyroid gland have also been described (Endres 2022).

Clinical features
This section has been translated automatically.

Hollenhorst plaques are generally asymptomatic (Ghoneim 2023). However, cases of transient monocular blindness also occur (Kaufman 2024).

Diagnostics
This section has been translated automatically.

The diagnosis is made on the basis of the patient's history and the characteristic findings of the retina on funduscopy (Mehta 2024). The HPs typically appear as yellowish fragments at an arterial bifurcation (Kaufman 2024). The Hollenhorst plaques show a characteristic refraction that makes them appear larger than the vessel (Augustin 2001).

In addition, once HPs have been diagnosed, the following tests can be used:

  • Blood test: Hypercoagulopathy should be excluded.
  • Blood pressure measurement to exclude arterial hypertension
  • Auscultation of the ipsilateral carotid artery for evidence of a murmur
  • ECG: Is there atrial fibrillation?
  • ECHO: Question about cardioembolic sources
  • CT or MRI 4- vessel carotid angiography: These examinations can be used to assess stenosis, dissection and / or dysplasia in more detail.
    • Fluorescein angiography: The following changes may be seen:
    • delayed or absent filling of the retinal artery (most specific sign)
    • prolonged arteriovenous transit time (most sensitive sign)
    • Capillary non-perfusion due to loss of endothelial cells, lumen obliteration and pericytes
    • Macular edema
    • Discoloration of the retinal vessels due to chronic ischemia
    • In the presence of ocular ischemic syndrome, hyperfluorescence is seen in the optic nerve pupil caused by leakage from the optic disc and capillaries (Kaufman 2024)

Differential diagnosis
This section has been translated automatically.

  • Calcified emboli: These affect central retinal arteries. They appear whitish and are caused by calcifications of the heart valves or the aorta.
  • Valley emboli: These appear relatively small, occur parafoveally and are observed in patients with intravenous drug abuse and / or cocaine addiction.
  • Fibrin thrombocyte emboli: These are dull white fragments within a retinal arteriole. They originate from a carotid thrombus.
  • Septic emboli: These occur in the context of bacterial endocarditis.
  • Air emboli
  • Fat emboli: These are found particularly after fractures of long bones. They are associated with isolated retinal hemorrhages and microinfarcts.
  • Amniotic fluid embolisms
  • Metastatic tumor cells (Kaufman 2024)

Complication(s)
This section has been translated automatically.

  • Hollenhorst plaques are markers for cerebrovascular disease and increased mortality (Graff-Radford 2015).
  • Ocular ischemic syndrome (OIS) (Kaufman 2024)
  • Branch artery occlusion (AAV) (Erb 2011)
  • Retinal central retinal artery occlusion. The risk of suffering an apoplexy is particularly high in the first few weeks after a retinal artery occlusion (Mehta 2024).

General therapy
This section has been translated automatically.

Treatment of the HPs is not necessary. The complete blockage of a vessel is an exception (Kaufman 2024). If complications occur, appropriate treatment should be administered immediately (Kaufman 2024).

Progression/forecast
This section has been translated automatically.

Asymptomatic HPs are a poor predictor of future embolic events. They are definitely a risk variable for apoplexy, as a meta-analysis of 1,343 asymptomatic patients shows. 17.8% had a current history of apoplexy or TIA. During follow-up, 12% suffered an apoplexy, TIA or died (Kaufman 2024).

Note(s)
This section has been translated automatically.

Patients with retinal embolisms should be referred to their GP for a bilateral carotid duplex examination. They should also be informed about appropriate lifestyle changes and how to combat risk factors such as arterial hypertension, diabetes mellitus, hyperlipidemia, obesity, lack of exercise and cigarette smoking (Kaufman 2024).

Literature
This section has been translated automatically.

  1. Augustin A J (2001) Ophthalmology. Springer Verlag Berlin / Heidelberg 1309
  2. Endres S (2022) Specialist examination in internal medicine in cases, questions and answers. Elsevier Urban und Fischer Verlag Germany 417
  3. Erb C, Schlote T (2011) Drug eye therapy. Georg Thieme Verlag Stuttgart 283 - 285
  4. Ghoneim B M, Westby D, Walsh S R, Sagte M, Eisharkawi M (2023) Systematic review of the relationship between Hollenhorst plaques and cerebrovascular events. Vascular. 32 (4) 784 - 791 DOI: 10.1177/17085381231163339
  5. Graff- Radford J, Boes C J, Brown R D (2015) History of Hollenhorst plaques. Stroke. 46 (4) doi: https://doi.org/10.1161/STROKEAHA.114.007771
  6. Herold G et al (2020) Internal medicine. Herold Publishing House 840
  7. Hollenhorst RW (1961) Significance of bright plaques in the retinal arterioles. Trans Am Ophthalmol Soc 59. 252 - 273
  8. Kasper D L, Fauci A S, Hauser S L, Longo D L, Jameson J L, Loscalzo J et al. (2015) Harrison's Principles of Internal Medicine. Mc Graw Hill Education 201, 40e- 4
  9. Kaufman E J, Mahabadi N, Munakomi S, Patel B C (2024) Hollenhorst Plaque. StatPearls Treasure Island Bookshelf ID: NBK470445
  10. Mehta S (2024) Retinal central retinal artery occlusion and branch retinal artery occlusion. MSD Manual, edition for medical professionals. doi: https://www.msdmanuals.com/de-de/profi/augenkrankheiten/netzhauterkrankungen/retinaler-zentralarterienverschluss-und-arterienastverschluss

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Last updated on: 20.09.2024